News BIND accepts Pfizer bid following bankruptcy Bid of $20 million may be enough to acquire all of BIND's assets.
Articles Celgene’s new CEO weighs in to drug pricing debate Celgene's new CEO Mark Alles discusses pricing and M&A, criticises Valeant's approach. Richard Staines reports.
Articles Pharma news round-up: Pfizer-Allergan merger scrapped, Gilea... A round-up of this week's top pharma and healthcare news – plus reaction from social media. Marco Ricci reports.
Articles UCB: growing sales and growing bones The specialist pharma company is set to expand into osteoporosis through its partnership with Amgen
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
